Tirzepatide

People run it for fat loss and, in the diabetic world, for blood-sugar control — and it delivers both hard. The standout reported effects are strong appetite suppression and a sharp drop in “food noise,” with trial weight loss landing between the single-receptor drugs and the triple agonist. Unlike most peptides on this site, the use people run it for is the use it was actually trialed and approved for.

Its identity is the receptor ladder the community recites constantly: semaglutide hits one receptor (GLP-1), tirzepatide hits two (GLP-1 plus GIP), retatrutide hits three (adding glucagon). That second switch — GIP — is what separates it from the semaglutide generation, and in the one head-to-head trial that exists it translated into real-world superiority: roughly 20% body-weight loss versus ~14% for semaglutide at 72 weeks. It’s the “two receptors, not one” story made concrete, and it’s the most-trialed compound here by a wide margin.

A dual agonist: it activates both the GLP-1 and the GIP receptors. GLP-1 activation drives appetite suppression, slowed gastric emptying, and glucose-dependent insulin release; adding GIP-receptor activation appears to amplify the insulin and weight effects beyond what a GLP-1 drug alone achieves — though the GIP arm is pharmacologically “imbalanced” and biased, not a clean second copy of GLP-1. What it lacks, relative to retatrutide, is the third switch: there’s no glucagon-receptor activation here, which is why it’s both less powerful and easier on the body — no glucagon-driven heart-rate bump — than the triple agonist.

Gastrointestinal effects dominate, as with the whole class: nausea, constipation, diarrhea, and reflux, worst right after a dose increase and usually fading as the body adjusts — which is the entire reason for the slow titration. Notably, it lacks retatrutide’s signature elevated heart rate, because there’s no glucagon-receptor load. The biggest concern people raise isn’t the GI misery but muscle loss during rapid weight loss: trial body-composition data put roughly a quarter of the weight lost as lean mass (similar in proportion to placebo, but on a much bigger total), so protein intake and resistance training are the constant refrain to protect muscle. Class-level cautions apply — pancreatitis, gallbladder issues, and a boxed thyroid-tumor warning carried from rodent data — and it’s not for anyone with a personal or family history of medullary thyroid carcinoma.

In practice it’s run standalone for fat loss — there’s no community peptide-stacking protocol for it. When people say “stack” around tirzepatide they almost always mean the support around it, not other compounds: high protein and resistance training to protect muscle during fast loss, plus electrolytes and micronutrients. The work is in the diet and training alongside it, not in pairing it with another vial.